RUDACURE

R&D Pipeline

Development Stage

RUDACURE

RudaCure Co., Ltd. develops treatments for diseases with sensory based disorders and high unmet needs. Pipeline is divided into treatments via Rac1 inhibition and TRPV1 antagonism. Programs targeting Rac1 include treatments for Dry Eye, Corneal Ulcers, Atopic Dermatitis, Psoriasis, Melanoma and Wet-AMD. Programs targeting TRPV1 include treatments for chronic pain indications such as osteoarthritis pain and, chemotherapy induced peripheral neuropathy (CIPN) and CRPS.

Development Stage

RUDACURE

Rudacure Co., Ltd. develops ophthalmic diseases such as dry eye syndrome, senile macular degeneration, and develops neurological and cancerous pain.
We are focusing on developing painkillers, and five new drug pipelines are currently under development.

RCI001

RCI002

{"google":["Noto Sans","Poppins"],"custom":["Nanum Square","Nanum Barun Gothic","Noto Sans KR"]}

{"google":["Noto Sans","Poppins","Roboto","Oswald"],"custom":["Nanum Square","Nanum Barun Gothic","Noto Sans KR"]}

Company Name RudaCure Co., Ltd ｜ CEO Yong Ho Kim ｜ CPO Seunghoon Kim
Location
HQ&Research Institute R302, BRC1, 9, Songdomirae-ro, Yeonsu-gu, Incheon, Republic of Korea
Seoul Office R1001, 145, Gasan digital 1-ro, Geumcheon-gu, Seoul, Republic of Korea
US Office 40W, 37th St. Suite 801 New York, NY 10018
Corportate registration number 548-86-00995

{"google":[],"custom":["Noto Sans KR"]}